NR 546 MIDTERM EXAM 2026/2027 | Psychopharmacology
for Psychiatric-Mental Health NP | Questions & Verified
Answers | Chamberlain | Pass Guaranteed - A+ Graded
Section 1: Neurobiology & Neurotransmitters (Questions 1-12)
Q1. The mesolimbic dopamine pathway originates in the ventral tegmental area (VTA)
and projects primarily to the:
A. Prefrontal cortex, regulating executive function and cognition
B. Basal ganglia, controlling motor movement and coordination
C. Nucleus accumbens, mediating reward, motivation, and pleasure [CORRECT]
D. Hypothalamus, modulating autonomic and endocrine function
Rationale: The mesolimbic pathway (VTA → nucleus accumbens) is the brain's primary
reward circuit. Hyperactivity here is implicated in positive symptoms of schizophrenia
and addiction. The mesocortical pathway (A) projects to PFC and is associated with
negative symptoms/cognition when underactive. The nigrostriatal pathway (B) projects
to basal ganglia and controls motor function. The tuberoinfundibular pathway (D)
projects to the hypothalamus/pituitary and regulates prolactin. Understanding these
distinct projections is foundational to predicting antipsychotic side effects based on
receptor blockade patterns.
Correct Answer: C
,Q2. In the serotonin synthesis pathway, which intermediate compound is formed
immediately before 5-HT (serotonin)?
A. Tryptophan
B. 5-Hydroxytryptophan (5-HTP) [CORRECT]
C. 5-Hydroxyindoleacetic acid (5-HIAA)
D. Tyrosine
Rationale: The serotonin synthesis cascade is: Tryptophan → 5-HTP → 5-HT → 5-HIAA.
5-HTP is the direct precursor to serotonin, formed by tryptophan hydroxylase and then
converted to 5-HT by aromatic L-amino acid decarboxylase. Tryptophan (A) is the
dietary amino acid starting point. 5-HIAA (C) is the metabolite, not the precursor.
Tyrosine (D) is the precursor for catecholamines (dopamine, norepinephrine), not
serotonin. This pathway explains why 5-HTP supplements theoretically increase
serotonin but are not first-line due to lack of regulation and potential serotonin
syndrome risk.
Correct Answer: B
Q3. Which neurotransmitter is the primary excitatory neurotransmitter in the central
nervous system, and its hypofunction at NMDA receptors is hypothesized to contribute
to schizophrenia pathophysiology?
A. GABA
B. Glycine
C. Glutamate [CORRECT]
D. Acetylcholine
Rationale: Glutamate is the brain's primary excitatory neurotransmitter. The glutamate
hypothesis of schizophrenia proposes that NMDA receptor hypofunction (particularly on
GABA interneurons) leads to disinhibition of glutamatergic pyramidal neurons, causing
excessive dopamine release in the mesolimbic pathway. GABA (A) is the primary
inhibitory neurotransmitter. Glycine (B) is a co-agonist at NMDA receptors but not the
,primary excitatory transmitter. Acetylcholine (D) is involved in memory and attention; its
deficiency characterizes Alzheimer's disease, not schizophrenia's glutamatergic model.
Correct Answer: C
Q4. Blockade of which dopamine pathway by antipsychotic medications is responsible
for the therapeutic reduction of positive symptoms (hallucinations, delusions) in
schizophrenia?
A. Mesocortical pathway
B. Mesolimbic pathway [CORRECT]
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Rationale: Excessive dopaminergic activity in the mesolimbic pathway drives positive
symptoms (hallucinations, delusions, disorganized thought). D2 antagonism here
produces antipsychotic efficacy. Mesocortical pathway (A) hypodopaminergia causes
negative symptoms; blockade worsens cognition and negative symptoms. Nigrostriatal
pathway (C) blockade causes extrapyramidal symptoms (EPS). Tuberoinfundibular
pathway (D) blockade causes hyperprolactinemia. The Vermillion NR546 curriculum
emphasizes that no currently available antipsychotic selectively blocks only the
mesolimbic pathway, which is why EPS and prolactin elevation remain significant side
effects.
Correct Answer: B
Q5. The HPA axis dysregulation hypothesis in major depressive disorder involves
chronic elevation of which hormone, leading to hippocampal atrophy and reduced
neurogenesis?
A. Thyroid-stimulating hormone (TSH)
B. Cortisol [CORRECT]
C. Growth hormone
D. Insulin
, Rationale: Chronic HPA axis hyperactivity in depression results in sustained cortisol
elevation, which is neurotoxic to the hippocampus (rich in glucocorticoid receptors),
impairs neurogenesis, and reduces brain-derived neurotrophic factor (BDNF). This
explains the association between chronic stress, depression, and cognitive impairment.
TSH (A) regulates thyroid function. Growth hormone (C) and insulin (D) are not primary
HPA axis hormones. The NR546 curriculum links this neurobiological mechanism to
why antidepressants that increase BDNF and neuroplasticity require weeks to show
clinical effect.
Correct Answer: B
Q6. BDNF (brain-derived neurotrophic factor) exerts its neurotrophic effects primarily
through which receptor?
A. NMDA receptor
B. GABA-A receptor
C. TrkB receptor [CORRECT]
D. D2 receptor
Rationale: BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, activating
intracellular signaling cascades that promote neuronal survival, differentiation, and
synaptic plasticity. This pathway is downregulated in depression and upregulated by
antidepressant treatment. NMDA (A) is an ionotropic glutamate receptor. GABA-A (B) is
the primary inhibitory receptor. D2 (D) is a dopamine receptor. Understanding
BDNF-TrkB signaling explains the delayed onset of antidepressant action and the
rationale for novel rapid-acting treatments like ketamine that acutely increase BDNF.
Correct Answer: C
Q7. Which second messenger system is activated when norepinephrine binds to alpha-1
adrenergic receptors?
A. Decreased cAMP via inhibitory G-protein (Gi)
for Psychiatric-Mental Health NP | Questions & Verified
Answers | Chamberlain | Pass Guaranteed - A+ Graded
Section 1: Neurobiology & Neurotransmitters (Questions 1-12)
Q1. The mesolimbic dopamine pathway originates in the ventral tegmental area (VTA)
and projects primarily to the:
A. Prefrontal cortex, regulating executive function and cognition
B. Basal ganglia, controlling motor movement and coordination
C. Nucleus accumbens, mediating reward, motivation, and pleasure [CORRECT]
D. Hypothalamus, modulating autonomic and endocrine function
Rationale: The mesolimbic pathway (VTA → nucleus accumbens) is the brain's primary
reward circuit. Hyperactivity here is implicated in positive symptoms of schizophrenia
and addiction. The mesocortical pathway (A) projects to PFC and is associated with
negative symptoms/cognition when underactive. The nigrostriatal pathway (B) projects
to basal ganglia and controls motor function. The tuberoinfundibular pathway (D)
projects to the hypothalamus/pituitary and regulates prolactin. Understanding these
distinct projections is foundational to predicting antipsychotic side effects based on
receptor blockade patterns.
Correct Answer: C
,Q2. In the serotonin synthesis pathway, which intermediate compound is formed
immediately before 5-HT (serotonin)?
A. Tryptophan
B. 5-Hydroxytryptophan (5-HTP) [CORRECT]
C. 5-Hydroxyindoleacetic acid (5-HIAA)
D. Tyrosine
Rationale: The serotonin synthesis cascade is: Tryptophan → 5-HTP → 5-HT → 5-HIAA.
5-HTP is the direct precursor to serotonin, formed by tryptophan hydroxylase and then
converted to 5-HT by aromatic L-amino acid decarboxylase. Tryptophan (A) is the
dietary amino acid starting point. 5-HIAA (C) is the metabolite, not the precursor.
Tyrosine (D) is the precursor for catecholamines (dopamine, norepinephrine), not
serotonin. This pathway explains why 5-HTP supplements theoretically increase
serotonin but are not first-line due to lack of regulation and potential serotonin
syndrome risk.
Correct Answer: B
Q3. Which neurotransmitter is the primary excitatory neurotransmitter in the central
nervous system, and its hypofunction at NMDA receptors is hypothesized to contribute
to schizophrenia pathophysiology?
A. GABA
B. Glycine
C. Glutamate [CORRECT]
D. Acetylcholine
Rationale: Glutamate is the brain's primary excitatory neurotransmitter. The glutamate
hypothesis of schizophrenia proposes that NMDA receptor hypofunction (particularly on
GABA interneurons) leads to disinhibition of glutamatergic pyramidal neurons, causing
excessive dopamine release in the mesolimbic pathway. GABA (A) is the primary
inhibitory neurotransmitter. Glycine (B) is a co-agonist at NMDA receptors but not the
,primary excitatory transmitter. Acetylcholine (D) is involved in memory and attention; its
deficiency characterizes Alzheimer's disease, not schizophrenia's glutamatergic model.
Correct Answer: C
Q4. Blockade of which dopamine pathway by antipsychotic medications is responsible
for the therapeutic reduction of positive symptoms (hallucinations, delusions) in
schizophrenia?
A. Mesocortical pathway
B. Mesolimbic pathway [CORRECT]
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Rationale: Excessive dopaminergic activity in the mesolimbic pathway drives positive
symptoms (hallucinations, delusions, disorganized thought). D2 antagonism here
produces antipsychotic efficacy. Mesocortical pathway (A) hypodopaminergia causes
negative symptoms; blockade worsens cognition and negative symptoms. Nigrostriatal
pathway (C) blockade causes extrapyramidal symptoms (EPS). Tuberoinfundibular
pathway (D) blockade causes hyperprolactinemia. The Vermillion NR546 curriculum
emphasizes that no currently available antipsychotic selectively blocks only the
mesolimbic pathway, which is why EPS and prolactin elevation remain significant side
effects.
Correct Answer: B
Q5. The HPA axis dysregulation hypothesis in major depressive disorder involves
chronic elevation of which hormone, leading to hippocampal atrophy and reduced
neurogenesis?
A. Thyroid-stimulating hormone (TSH)
B. Cortisol [CORRECT]
C. Growth hormone
D. Insulin
, Rationale: Chronic HPA axis hyperactivity in depression results in sustained cortisol
elevation, which is neurotoxic to the hippocampus (rich in glucocorticoid receptors),
impairs neurogenesis, and reduces brain-derived neurotrophic factor (BDNF). This
explains the association between chronic stress, depression, and cognitive impairment.
TSH (A) regulates thyroid function. Growth hormone (C) and insulin (D) are not primary
HPA axis hormones. The NR546 curriculum links this neurobiological mechanism to
why antidepressants that increase BDNF and neuroplasticity require weeks to show
clinical effect.
Correct Answer: B
Q6. BDNF (brain-derived neurotrophic factor) exerts its neurotrophic effects primarily
through which receptor?
A. NMDA receptor
B. GABA-A receptor
C. TrkB receptor [CORRECT]
D. D2 receptor
Rationale: BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, activating
intracellular signaling cascades that promote neuronal survival, differentiation, and
synaptic plasticity. This pathway is downregulated in depression and upregulated by
antidepressant treatment. NMDA (A) is an ionotropic glutamate receptor. GABA-A (B) is
the primary inhibitory receptor. D2 (D) is a dopamine receptor. Understanding
BDNF-TrkB signaling explains the delayed onset of antidepressant action and the
rationale for novel rapid-acting treatments like ketamine that acutely increase BDNF.
Correct Answer: C
Q7. Which second messenger system is activated when norepinephrine binds to alpha-1
adrenergic receptors?
A. Decreased cAMP via inhibitory G-protein (Gi)
